The certified gene list and inheritance fields are empty in this packet, so the genetic basis and inheritance pattern are not specified here. No cause or mechanism is certified beyond the classification of the condition as a lymphoma of T cells affecting the skin.

Diagnostic methods are not certified in this packet, and no newborn screening information is supplied.

Treatment coverage in this packet is limited to regulatory records. Five products appear in the packet's approved-treatment records with active market status: methotrexate (JYLAMVO), cyclophosphamide, mogamulizumab-kpkc (POTELIGEO), mechlorethamine hydrochloride (VALCHLOR) and brentuximab vedotin (ADCETRIS). Orphan drug records list VALCHLOR and ADCETRIS with approved status and an indication of mycosis fungoides. Other orphan drug records carry designated status, including candidates with a mycosis fungoides or cutaneous T-cell lymphoma indication; designation is not approval and these are described only as under development. Stage-specific treatment planning, care-team structure and treatment intent are not described in the certified fields.

Prognosis is not certified in this packet, and no survival figures are supplied.

Numerous certified active trial records are present. Examples include ultra low dose radiation therapy in mycosis fungoides (NCT03398161, Phase 2, M.D. Anderson Cancer Center), extracorporeal photopheresis and mogamulizumab in erythrodermic cutaneous T-cell lymphoma (NCT04930653, Phase 2, City of Hope Medical Center), PTX 100 in relapsed or refractory cutaneous T-cell lymphoma (NCT06854653, Phase 2, Prescient Therapeutics), and a study of mogamulizumab-associated rash (NCT07003100). Trial titles do not establish what an intervention does or whether it is effective. Active clinical trials for this condition are listed on ClinicalTrials.gov.